Advanced search
Publication Cover
Acta Cardiologica Volume 79, 2024 - Issue 1
Submit an article Journal homepage
2,615
Views
8
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study

Philippe van de Bornea Department of Cardiology, Erasme Hospital, University Libre of Brussels, Brussels, BelgiumCorrespondence[email protected]
View further author information
,
André Peetersb Department of Neurology, Saint Luc University Clinic, Brussels, BelgiumView further author information
,
Luc Janssensc Department of Cardiology, Imelda Hospital, Bonheiden, BelgiumView further author information
,
Attilio Leoned Department of Cardiology, Tivoli University Hospital Centre, La Louvière, BelgiumView further author information
,
Robin Lemmense Department of Neurology, University Hospitals Leuven and KU Leuven, Leuven, BelgiumView further author information
,
Ann Verhaegenf Department of Endocrinology, Diabetes and Metabolism, Antwerp University Hospital, Edegem, BelgiumView further author information
,
Marc De Meulemeesterg GP, Private Practice, Gozée, BelgiumView further author information
,
Yohan Balthazarh GP, Private Practice, Natoye, BelgiumView further author information
,
Stéphane Heijmansi GP, Private Practice, Linkebeek, BelgiumView further author information
,
Yvan Calozetj GP, Private Practice, Gribomont, BelgiumView further author information
,
Nicolas Paquotk Department of Diabetology, Nutrition and Metabolic Diseases, Sart Tilman University Hospital Center, Liège, BelgiumView further author information
,
Stéphane Carlierl Department of Cardiology, Ambroise Paré Hospital and University of Mons (UMONS), Mons, BelgiumView further author information
,
Dimitri Hemelsoetm Department of Neurology, Ghent University Hospital, Ghent, BelgiumView further author information
,
Sarah Brayn Global Biostatistical Science, Amgen Ltd, Cambridge, UKView further author information
&
Kausik K. Rayo Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, London, UKView further author information
 show all
Pages 20-29 | Received 31 May 2021, Accepted 11 Jan 2022, Published online: 20 Apr 2022

References

  • OECD. Belgium: Country health profile 2017. 2017 [Accessed 9 Feb 2021]. Available from: https://www.oecd.org/belgium/belgium-country-health-profile-2017-9789264283299-en.htm
  • Renard F, Tafforeau J, Deboosere P. Premature mortality in Belgium in 1993-2009: leading causes, regional disparities and 15 years change. Arch Public Health. 2014;72(1):34.
  • Cordon A, De Meester C, Gerkens S, et al. Statins for the primary prevention of cardiovascular events. Health Technology Assessment (HTA) Brussels. KCE Reports 306. Belgian Health Care Knowledge Centre (KCE); 2019.
  • Di Angelantonio E, Sarwar N, Perry P, et al.; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009;302(18):1993–2000.
  • Lewington S, Whitlock G, Clarck R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a Meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. The Lancet. 2007;370:1829–1839.
  • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a Meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
  • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
  • Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
  • Catapano AL, Graham I, De Backer G, et al.; ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
  • Devroey D, Radermecker RP, Van der Schueren BJ, et al. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the dyslipidaemia international study (DYSIS). Int J Clin Pract. 2014;68(2):180–187.
  • Kotseva K, De Backer G, De Bacquer D, et al.; on behalf of the EUROASPIRE Investigators*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the european society of cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiolog. 2019;26(8):824–835.
  • Kjeldsen SE. Hypertension and cardiovascular risk: General aspects. Pharmacol Res. 2018;129:95–99.
  • Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246–1258.
  • Van der Niepen P, Thijs V, Devroey D, et al. Belgian global implementation of cardiovascular and stroke risk assessment study: methods and baseline data of the BELGICA-STROKE STUDY. Eur J Cardiovasc Prev Rehabil. 2011;18(4):635–641.
  • Leeman M, Dramaix M, Van Nieuwenhuyse B, et al. Cross-sectional survey evaluating blood pressure control ACHIEVEment in hypertensive patients treated with multiple anti-hypertensive agents in Belgium and Luxembourg. PLoS One. 2018;13(11):e0206510.
  • Borne PVD, Missault L, Persu A, et al. The COMmon control of hypErtenSion and therapeutic attitudes in BelgIum and luxemburg study (COME STAI). Acta Cardiol. 2016;71(1):35–40.
  • Van Casteren VF, Bossuyt NH, Moreels SJ, et al. Does the belgian diabetes type 2 care trajectory improve quality of care for diabetes patients? Arch Public Health. 2015;73(1):31.
  • Ray K, Molemans B, Schoonen W, et al.; the DA VINCI study. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prevent Cardiol. 2021;28(11):1279–1289.
  • Conroy R, Pyörälä K, Fitzgerald A, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003.
  • Wilson PW, D'Agostino R, Sr., Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695–703.e1.
  • Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
  • Pradhan A, Bhandari M, Sethi R. Ezetimibe and improving cardiovascular outcomes: current evidence and perspectives. Cardiol Res Pract. 2020;2020:9815016.
  • Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a european atherosclerosis society task force. Atherosclerosis. 2021;325:99–109.
  • Poredos P, Jezovnik MK. Do the effects of secondary prevention of cardiovascular events in PAD patients differ from other atherosclerotic disease? Int J Mol Sci. 2015;16(7):14477–14489.
  • Mohler ER, 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481–1486.
  • Wang Y, Xu D. Effects of aerobic exercise on lipids and lipoproteins. Lipids Health Dis. 2017;16(1):132.
  • Choudhury KN, Mainuddin AKM, Wahiduzzaman M, et al. Serum lipid profile and its association with hypertension in Bangladesh. Vas Health Risk Manage. 2014;10:327–332.
  • Osuji CU, Omejua EG, Onwubuya EI, et al. Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria. Int J Hypertens. 2012;2012:710486.
  • Herink M, Ito MK. Medication induced changes in lipid and lipoproteins [updated 2018 May 10]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326739/
  • Goossens M, Kalyvas C, Kennel T, et al. De zorgtrajecten diabetes mellitus type 2 en chronische nierinsufficiëntie en kwaliteit van zorg. Brussel: Sciensano. Depotnummer; 2017–2019.
Novo Nordisk – Driving change to defeat serious chronic diseases.
A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.